Dostarlimab for the treatment of advanced endometrial cancer

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   Google Scholar
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591.
   Google Scholar
• Lu KH, Broaddus RR. Endometrial Cancer. N Engl J Med. 2020;383(21):2053–2064.
   Google Scholar
• Getz G, Gabriel SB, Cibulskis K, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
   Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113:299–310.
   Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123:802–813.
   Google Scholar
• Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29:1180–1188.
   Google Scholar
• Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 31(1): 12–39. 2021.
   Google Scholar
• Piulats JM, Matias-Guiu X. Immunotherapy in endometrial cancer: in the Nick of time. Clin Cancer Res. 2016;22(23):5623–5625.
   Google Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–1285.
   Google Scholar
• Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–3850.
   Google Scholar
• Connor EV, Rose PG. Management strategies for recurrent endometrial cancer. Expert Rev Anticancer Ther. 2018;18(9):873–885.
   Google Scholar
• Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964–978.
   Google Scholar
• Jerzak KJ, Duska L, MacKay HJ. Endocrine therapy in endometrial cancer: an old dog with new tricks. Gynecol Oncol. 2019;153(1):175–183.
   Google Scholar
• Mirza MR, Bjørge L, and Marmé F, et al. A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptorpositive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO/ENGOT-EN3 trial. Presented at: European Society of Medical Oncology (ESMO) Virtual Congress ; 2020 Sep 19-21. 2020 Sep 19-21.
   Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372(26): 2509–2520. 2015.
   Google Scholar
• Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758.
   Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.
   Google Scholar
• Soumerai TE, Donoghue MTA, Bandlamudi C, et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res. 2018;24(23):5939–5947.
   Google Scholar
• Aird JJ, Steel MJ, Chow C, et al. Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts. Histopathology. 2020;76(4):521–530.
   Google Scholar
• Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, et al. Immune checkpoint inhibitors in endometrial cancer. Crit Rev Oncol Hematol. 2021;161:103306.
   Google Scholar
• Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–2541.
   Google Scholar
• Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 37(30): 2786–2794. 2019.
   Google Scholar
• Antill Y, Kok PS, Robledo K, et al. Australia New Zealand Gynaecological Oncology Group (ANZGOG). Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 9(6): e002255. 2021.
   Google Scholar
• Bellone S, Roque DM, Siegel ER, et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Ann Oncol. 2021;32(8):1045–1046.
   Google Scholar
• Lheureux S, Matei D, and Konstantinopoulos PA, et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. Presented at: American Society of Clinical Oncology (ASCO) Annual Virtual Meeting ; 2020 May 29-31. 2020 May 29-31.
   Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20(5): 711–718. 2019.
   Google Scholar
• Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 38(26): 2981–2992. 2020.
   Google Scholar
• Arora S, Balasubramaniam S, Zhang W, et al. FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis. Clin Cancer Res. 2020;26(19):5062–5067.
   Google Scholar
• Makker V, Colombo N, Casado Herráez A, et al. A multicenter, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/KEYNOTE-775. Presented at: Society of Gynecologic Oncology (SGO) Virtual Annual Meeting on Women’s Cancer; 2021 Mar 18-21. Abstract 37/ID 11512.
   Google Scholar
• Makker V, Colombo N, and Casado Herráez A, et al. Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (AEC): subgroup analysis of patients with DNA mismatch repair deficient (dMMR) tumors. Presented at: International Gynecologic Cancer Society (IGCS) Global Meeting Rome; 2021 Aug 30-Sep 2. Abstract 43.
   Google Scholar
• Laken H, Kehry M, McNeeley P, et al. Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody. Eur J Cancer. 2016;69(Suppl 1):S102.
   Google Scholar
• GlaxoSmithKline. Jemperli (Dostarlimab): US prescribing information; [cited 2021 Aug 08]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf
   Google Scholar
• Jemperli European Public Assessment Report (EPAR). Committee for medicinal products for human use (CHMP). European Medicines Agency. [cited 2021 Feb 25]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/jemperli-epar-public-assessment-report_en.pdf
   Google Scholar
• Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 6(11): 1766–1772. 2020.
   Google Scholar
• Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from GARNET. Presented at: European Society of Medical Oncology (ESMO) Congress. 2020 Sept 19-21. Abstract LBA36.
   Google Scholar
• Oaknin A, Gilbert L, and Tinker AV, et al. Antitumor activity of dostarlimab in patients with advanced or recurrent mismatch repair–deficient or proficient–cancer by prior therapy: results from the GARNET study. Presented at: International Gynecologic Cancer Society (IGCS) Global Meeting Rome; 2021 Aug 30-Sep 2. Abstract 149.
   Google Scholar
• Oaknin A, Gilbert L, Tinker AV, et al. Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study. Presented at: Society of Gynecologic Oncology (SGO) Virtual Annual Meeting on Women’s Cancer; 2021 Mar 18-21. Abstract LBA36.
   Google Scholar
• Oaknin A, Gilbert L, and Tinker AV, et al. Activity of dostarlimab by tumor mutational burden in patients with endometrial cancer in the GARNET trial. Presented at: European Society of Medical Oncology (ESMO) Congress Paris. 2021 Sep 16-21. 2021 Sep 16-21.
   Google Scholar
• Andre T, Berton D, Curigliano G, et al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) Virtual Annual Meeting. 2021 Jan 15-17. Abstract 9.
   Google Scholar
• Kristeleit R, Matthews C, Redondo A, et al. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab. Presented at: European Society of Medical Oncology (ESMO) Virtual Congress; 2020 Sep 19-21. Abstract 858P.
   Google Scholar